Markets Surge on Tech Trade, "Not Critical" Tariffs
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NIKE, Inc. (NKE) : Free Stock Analysis Report
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
Palantir Technologies Inc. (PLTR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Connectez-vous pour accéder à votre portefeuille
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
12 minutes ago
- NBC News
Trump says Treasury Secretary Bessent 'does not want' to be Fed chair, but 4 others in running
President Donald Trump told CNBC on Tuesday that he has narrowed the field of potential future Federal Reserve chairs to four candidates, a list that does not include Treasury Secretary Scott Bessent. While the president did not disclose who is in contention, he revealed that Bessent, previously considered a leading candidate, has taken himself out of contention. 'Well, I love Scott, but he wants to stay where he is,' Trump said during a ' Squawk Box ' interview. 'I asked him just last night, 'Is this something you want?' [Bessent said], 'Nope, I want to stay where I am. He actually said, 'I want to work with you.' It's such an honor. I said, 'That's very nice. I appreciate that.'' The news follows Fed Governor Adriana Kugler's surprise announcement Friday that she is resigning effective this Friday. The move allows Trump to install another of his appointees to the Fed Board of Governors at a time when the White House is aggressively pushing the central bank to lower interest rates. Among the likely candidates remaining are former Governor Kevin Warsh and Kevin Hassett, the National Economic Council director and a key Trump advisor. Both have advocated for lower rates. Fed Governor Christopher Waller also is thought to be in the running. 'Both Kevins are very good, and there are other people that are very good, too,' Trump said, adding that Kugler's resignation 'was a pleasant surprise.' Current Chair Jerome Powell 's term ends in May 2026. He has been a frequent target of Trump's criticism, and there has been speculation that the president would name a 'shadow chair' who could help undermine Powell until his term expires. Trump did not commit to taking that approach but conceded that it is 'a possibility.' Trump nominated Powell for the Fed job in 2017, during his first term as president. The Senate then confirmed Powell the following February. Trump alleged Tuesday that Powell told him, 'Sir, I'll keep interest rates so low. I'm a low interest rate person.' The Fed last week voted to hold its benchmark interest rate steady in a range between 4.25%-4.5%. Markets expect the Fed to approve its next cut in September. The central bank lowered its policy rate a full percentage point from September through December 2024, moves that Trump has said were politically motivated to help Democratic presidential nominee Kamala Harris. Click here to watch the CNBC TV livestream.
Business Wire
12 minutes ago
- Business Wire
Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Investors with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers and acquirers of Novo Nordisk A/S (NYSE: NVO) securities between May 7, 2025 and July 28, 2025, both dates inclusive (the 'Class Period'). Novo Nordisk is a pharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Novo Nordisk A/S (NYSE: NVO) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo Nordisk's growth potential. Notably, Novo Nordisk's asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood that such patients would switch to Novo Nordisk's branded alternatives. Further, defendants greatly overstated the potential GLP-1 market or otherwise, Novo's capability to penetrate said markets to achieve continued growth. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Novo Nordisk. Investors who want to serve as lead plaintiff for the class must file their motions with the court by September 30, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
CNBC
13 minutes ago
- CNBC
A technical look at Wall Street's 'fear gauge' and how to hedge against potential volatility
As Fundstrat's Tom Lee says, this is the most hated bull market of all time, yet it continues to power higher. There are plenty of overhanging uncertainties that could derail this rally that I'll discuss below, but first let's talk about technical condition of this rally. This V-shape recovery-turned-rally from April lows has been unrelenting. Any minor pullbacks are bought up and those left on the sideline are still waiting for a sizable pullback to enter. It could continue to power higher leaving those on the sideline chasing momentum and entries at new highs, or, the numerous overhanging threats to this market could begin to manifest and pullback may be ahead of us. We can't know. No one knows the future. All we can do is control our process in the present and plan accordingly. To avoid the concern that we need to be able to predict the future to successfully invest in the markets, we recently deployed a VIX hedge to our Active Opps portfolio at Inside Edge Capital with a favorable risk-reward ratio. If the market does pullback the VIX hedge will provide some protection to our portfolio while we're able to hold onto the strong names we've been building here with you every Tuesday on CNBC Pro. The S & P broke out from the late 2024 highs at around 6,140 and have not yet re-tested that breakout zone as support. It's not required, but it would be nice to see this checkback to this significant technical level. Also located in this zone is the 50 period moving average (dotted purple). You'll also notice the rate of change indicator below that has been in a decisive downtrend. To use a baseball analogy as I'm running travel baseball tryouts tonight, if you throw a ball in the air the speed of ascent will decelerate until the rate of change is zero and gravity takes over and pulls the ball back to the ground. The same thing here. At some point buyers will exhaust themselves and sellers will come in. Looking at the Volatility Index (VIX) overlay with the S & P 500 you'll notice that there is a clear inverse relationship between the two. As the stock market falls, fear and the accompanying price of option insurance goes up. Home insurance on a house with a smoldering foundation is going to be a lot more expensive than a calm clear day. The VIX at 17 is still relatively cheap so insurance is still reasonable. Plus you'll notice that I've outlined a divergence between late 2024 and now. With the S & P 500 at new highs, the VIX should be sub-15, but as mentioned above there are so many overhanging threats to the market investors are buying up the insurance policy keeping the VIX somewhat elevated. Specifically, we went to the VIX September monthly call options and bought the 23 strike and then sold the 29 call. The difference between the two should be around $1.50 for that $6 spread so that means you're risking $150 to make $450 if the VIX is above 29 on Sept. 17. As mentioned, there are threats to the market that we all know about including a Fed that may not be ready to drop rates despite many calling for it, persistent inflation driven by strong demand tariff pressures, Geopolitical tensions, narrowing breadth in the market as mega-cap hyper scalers are starting to lead once again, and finally seasonality. September is historically the worst month for the S & P 500. Hopefully we won't need the hedge and will close it at a loss. But if we do need it and the market is going to pullback, we can maintain our strong portfolio and not dislodge the low cost basis of names we've been building this year. -Todd Gordon, Founder of Inside Edge Capital, LLC We offer active portfolio management and regular subscriber updates like the idea presented above. DISCLOSURES: (Gordon owns VIX call spreads personally and in his wealth management company Inside Edge Capital) All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
